View Other Search Results
Books
Language
English
Books
Language
English
Books
Summary
In 2014, Theranos founder and CEO Elizabeth Holmes was widely seen as the female Steve Jobs: a brilliant Stanford dropout whose startup "unicorn" promised to revolutionize the medical industry with a machine that would make blood tests significantly faster and easier. Backed by investors such as Larry Ellison and Tim Draper, Theranos sold shares in a fundraising round that valued the company at $9 billion, putting Holmes's worth at an estimated $4.7 billion. There was just one problem: the technology didn't work. For years, Holmes had been misleading investors, FDA officials, and her own employees. When the author, working at The Wall Street Journal, got a tip from a former Theranos employee and started asking questions, both the author and the newspaper were threatened with lawsuits. Undaunted, the paper ran the first of dozens of Theranos articles in late 2015. By early 2017, the company's value was zero and Holmes faced potential legal action from the government and her investors. T
Electronic Access
More Info http://firstsearch.oclc.org/WebZ/DECRead?standardNoType=1&standardNo=152473165X&sessionid=0&srcdbname=worldcat&key=73338a4f9aef9cbc5912e927569e13104f3303dc8ba68e7759f2f172a8668bdb&ectype=MOREINFO Table of contents http://firstsearch.oclc.org/WebZ/DECRead?standardNoType=1&standardNo=152473165X&sessionid=0&srcdbname=worldcat&key=73338a4f9aef9cbc5912e927569e13104f3303dc8ba68e7759f2f172a8668bdb&ectype=TOC
Language
English
Audio disc
Summary
In 2015, Theranos founder and CEO Elizabeth Holmes was widely seen as the female Steve Jobs: a brilliant Stanford dropout whose startup "unicorn" promised to revolutionize the medical industry with a machine that would make blood tests significantly faster and easier. Backed by investors such as Larry Ellison and Tim Draper, Theranos sold shares in a fundraising round that valued the company at $9 billion, putting Holmes's worth at an estimated $4.7 billion. There was just one problem: the technology didn't work. For years, Holmes had been misleading investors, FDA officials, and her own employees. When the author, working at The Wall Street Journal, got a tip from a former Theranos employee and started asking questions, both the author and the newspaper were threatened with lawsuits. Undaunted, the paper ran the first of dozens of Theranos articles in late 2015. By early 2017, the company's value was zero and Holmes faced potential legal action from the government and her investors. T
Electronic Access
7.
Language
Vietnamese
Books
Summary
In 2014, Theranos founder and CEO Elizabeth Holmes was widely seen as the female Steve Jobs: a brilliant Stanford dropout whose startup "unicorn" promised to revolutionize the medical industry with a machine that would make blood tests significantly faster and easier. Backed by investors such as Larry Ellison and Tim Draper, Theranos sold shares in a fundraising round that valued the company at $9 billion, putting Holmes's worth at an estimated $4.7 billion. There was just one problem: the technology didn't work. For years, Holmes had been misleading investors, FDA officials, and her own employees. When the author, working at The Wall Street Journal, got a tip from a former Theranos employee and started asking questions, both the author and the newspaper were threatened with lawsuits. Undaunted, the paper ran the first of dozens of Theranos articles in late 2015. By early 2017, the company's value was zero and Holmes faced potential legal action from the government and her investors. T
8.
Language
Chinese
Original Title
坏血 : 一个硅谷巨头的秘密与谎言 / [美] 约翰・卡雷鲁 著 ; 成起宏 译 = Bad blood : secrets and lies in a Silicon Valley startup / John Carreyrou.
Books
9.
Language
Chinese
Original Title
惡血 : 矽谷獨角獸的醫療騙局! 深藏血液裡的祕密, 謊言與金錢 / 約翰・凱瑞魯著 ; 林錦慧譯 = Bad blood : secrets and lies in a Silicon Valley startup / John Carreyrou.
Books
Limit Search Results